ClinicalTrials.gg
TerminatedNCT04648202Updated Nov 5, 2026

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

A Phase 1 interventional study of FS120 in Advanced Cancer and Metastatic Cancer, sponsored by invoX Pharma Limited. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by invoX Pharma Limited (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Why this study was terminated
The study was terminated early due to a strategic business decision by the Sponsor, unrelated to safety.

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.
Updated Nov 5, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 415 studies in Neoplasm Metastasis with a site in Spain — 79 open to participants now, 144 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Enrollment
270th of 393
82 · median 163
Started
2020
with 23 others
Phase 1
94 of 415
15 open now
Registered
260th of 415
by date

Among the 415 studies in Neoplasm Metastasis with a site in Spain, this one is the 270th largest by enrollment of the 393 interventional ones that give a count, is one of 24 that started in 2020, is one of 94 in phase 1, and was the 260th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

79 of the 415 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer

Browse trials for

Keywords

  • Immuno-oncology
  • Bispecific antibody
  • Dose escalation
  • Cohort expansion
  • OX40
  • CD137 (4-1BB)
  • invoX
  • Pembrolizumab
  • PD-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status 0-1.
  • Highly effective if risk of conception exists
  • A female subject is eligible if not pregnant, not breastfeeding, not a woman of (WOCBP) or is a WOCBP that uses highly effective contraception
  • Subjects with who are healthy and how a low risk of acquired immunodeficiency syndrome related outcomes
  • For combination part: Subjects must have confirmed locally advanced, unresectable or solid tumours where there is regulatory approval for use of pembrolizumab as a monotherapy agent

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy within 28 days or 5- half-lives, whichever is shorter, before the first dose of study drug.
  • Prior therapy with any OX40 agonist, CD137 (4-1BB) agonist, 0 agonist, GITR, or CD27 targeting therapy (single agent or combination).
  • Prior radiotherapy within 2 weeks of start of study treatment.
  • infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  • Uncontrolled central nervous system (CNS) and/or carcinomatous meningitis, primary CNS tumours, or solid tumours with as the only .
  • Prior history of any grade ≥3 immune-related AE (irAE) that has not improved to grade ≤1; any grade ≥3 irAE that resulted in discontinuation of treatment, significant (grade ≥3 Version 5.0) treatment-related cytokine release syndrome.
  • Use of agents, or intolerance to monoclonal antibodies or their , persistent grade ≥1 NCI CTCAE Version 5 toxicity related to prior therapy or any condition that would significantly impair and/or prohibit the participant's participation in the study, as per the investigator's judgement.
  • Vaccination with a within 30 days before first dose of study drug.
  • Participants with a known additional that is progressing or has required active treatment in the past 3 years.
  • Participants with severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    FS120

    Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts

    Drug: FS120

Interventions

  • DrugFS120

    Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.

    Also known as: Pembrolizumab (KEYTRUDA®)

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and duration of adverse events (AEs), serious adverse events (SAEs) and dose limiting toxicities (DLTs)

    Safety and tolerability will be evaluated by collection of AEs, SAEs and DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: 24 months

  2. Determination of a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)

    Toxicity will be evaluated according to the NCI CTCAE Version 5.0.

    Time frame: 24 months

07

Study locations

9 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2020 to primary completion in Jan 2025, 50 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Mar 2026 → Jan 2025 and completion Mar 2026 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Dec 1, 2020
StartActual
Nov 18, 2020
Primary completionActual
Jan 24, 2025was Mar 2026
CompletionActual
Jan 24, 2025was Mar 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The study was terminated early due to a strategic business decision by the Sponsor, unrelated to safety.
changed Nov 5, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 Spain)
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
Show 4 removed
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
Nov 5, 2026
Primary completion
Mar 1, 2026→Jan 24, 2025 (actual)
Nov 5, 2026
Study completion
Mar 1, 2026→Jan 24, 2025 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Terminated
    Why stopped The study was terminated early due to a strategic business decision by the Sponsor, unrelated to safety.
    4 sites added, 4 sites removed
    Show 4 added (4 Spain)
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    Show 4 removed
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    Primary completion Mar 1, 2026→Jan 24, 2025 (now actual)
    Study completion Mar 1, 2026→Jan 24, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04648202
Responsible party
Sponsor
First posted
Dec 1, 2020
Start date
Nov 18, 2020
Primary completion
Jan 24, 2025
Completion
Jan 24, 2025
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion